Sign in
Taking people in United StatesPhase 1/2

Tests ST-067 alone or with pembrolizumab in adults with advanced solid tumors

Tests ST-067, alone or with pembrolizumab, in adults with advanced solid cancers.

Key facts

Who runs it
Simcha IL-18, Inc.
Where
Boston, Buffalo, Denver, New Haven, Scottsdale, and Tampa, United StatesSee the 6 sites
Trial code
Registry title
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status
Recruiting
Phase
Phase 1/2
People taking part
316 people, planned
Started
6 Aug 2021
Planned end
31 Dec 2025
Type of study
Interventional, 4 groups
Treatments tested
  • ST-067
  • Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]
  • pembrolizumab
Record updated
15 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an advanced or spread solid tumor that has got worse after standard treatment, or for whom no life-prolonging standard treatment is available.

Age
18 years or older
Sex
Men and women
Disease stage
Advanced or metastatic solid tumor confirmed by tissue tests. Allowed tumor types include melanoma, kidney cancer, triple-negative breast cancer, non-small cell lung cancer, head and neck squamous cell cancer and MSI-high tumors. The list is wider in Phase 1a. At least 1 measurable tumor that has not been biopsied or irradiated. A tumor that can be biopsied before and during treatment.
Earlier treatment
The disease has got worse through standard therapy, or no life-prolonging standard therapy is available or usable. No approved anticancer treatment or investigational drug within 4 weeks of Day 1. No live vaccine within 30 days. No major surgery within 4 weeks.
Biomarker or test result
Triple-negative breast cancer: no estrogen or progesterone receptor, and HER2 not 3+ or negative by FISH. MSI-high tumor: changes in 30% or more of microsatellites by PCR, or MSH1/2/6 or PMS-2 missing by IHC. High tumor mutation burden: 10 mut/Mb or greater. Lung cancer in combination dose escalation: no EGFR, TRK receptor or ALK mutations or fusions.

Main reasons for not taking part

  • History of another cancer
  • Active autoimmune disease, or ongoing immune-suppressing treatment including corticosteroids
  • Prior solid organ or bone marrow progenitor cell transplant
  • Ongoing infection, or serious heart or breathing problems
  • Symptomatic brain metastases needing more than 10 mg/day of prednisolone or equivalent

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Male and female patients aged ≥18 years
  • Must provide written informed consent and any authorizations required by local law
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Have histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumor; For Phase 1a, the following solid tumors are allowed: Melanoma, Merkel cell, RCC, urothelial, NSCLC,TNBC, SCCHN, microsatellite instability high, high tumor mutation burden (Hi TMB) or mismatch repair deficient, gastric, cervical, endometrial, cutaneous squamous, small cell lung, esophageal, hepatocellular carcinoma and platinum resistant ovarian cancer; For patients who have developed disease progression through standard therapy, or; For patients whom standard of care therapy that prolongs survival is unavailable or unsuitable (according to the investigator and after consultation with the Medical Monitor) For Phase 1 combination therapy dose escalation, the following solid tumors are allowed: Melanoma, Merkel cell, RCC, urothelial, NSCLC (with no EGFR, TRK receptor, or ALK positive mutations/fusions), TNBC, SCCHN, MSI-Hi tumors, Hi TMB or mismatch repair deficient, gastric, cervical, endometrial, cutaneous squamous, small cell lung, esophageal, and HCC; TNBC is diagnosed in a tumor which does not express estrogen receptor or progesterone receptor, is not human epidermal growth factor receptor 2 (HER2) 3+ on IHC or is negative by fluorescence in situ hybridization (FISH); MSI high tumor should have mutations in 30% or more microsatellites by PCR or be negative for MSH1/2/6 or PMS-2 by IHC; Hi-TMB high tumor has 10 mut/Mb or greater calculated from whole genome sequencing or whole exome sequencing; For Phase 2, the following solid tumors are allowed:; Melanoma, RCC, TNBC, NSCLC, SCCHN, and MSI-Hi tumors
  • Has at least 1 measurable lesion per RECIST 1.1 criteria which has not been biopsied or received prior irradiation
  • Has an accessible tumor for biopsy pre- and on-treatment (mandatory)

Who cannot take part

  • Significant cardiovascular disease (MI, thrombotic events,) within 6 months prior to study treatmentSignificant ECG abnormalities (Phase 1a and 2 monotherapy only) including unstable cardiac arrhythmia requiring medication, second-degree atrioventricular block type II, third degree AV
  • Has received a live vaccine within 30 days
  • Major surgery within 4 weeks
  • Prior solid organ or bone marrow progenitor cell transplantation
  • Prior high dose chemotherapy requiring stem cell rescue
  • Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids
  • Treatment with an approved, systemic anticancer therapy or an investigational agent within 4 weeks of Day 1
  • A positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral test within 28 days prior to dosing, unless there is Investigator-confirmed clinical recovery on or before C1D1
  • Presence of known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging, clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment
  • Prior radiotherapy within 2 weeks of start of study treatment or history of radiation pneumonitis
  • Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40, CD137), and was discontinued from that treatment due to a Grade 3 or higher irAE
  • Subjects that have received radiation therapy to the lung that is >30Gy within 6 months of the first dose of study treatment
  • History of another malignancy
  • Any degree of respiratory compromise (from either malignant or non-malignant disease)
  • Evidence of an ongoing systemic bacterial, fungal, or viral infection
  • History of active autoimmune disorders
  • Subjects with adrenal insufficiency
  • Presence of an active documented autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine or insulin) is not considered a form of systemic treatment and is allowed. Subjects may use topical and/or inhaled corticosteroids. However, subjects with adrenal insufficiency on replacement doses of steroids are not allowed
  • Severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients. Subjects who have been retreated after such a reaction may be allowed after discussion with the Simcha Medical Monitor
  • History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Subjects with any chemistry or hematology laboratory values that are ≥Grade 2; Additional exclusion criteria for Phase 1 combination therapy only:
  • Known symptomatic brain metastases requiring >10 mg/day of prednisolone or equivalent

Where in United States

  • Massachusetts General HospitalBoston, United StatesContact: Ryan Sullivan, MDTaking people
  • Roswell Park Cancer InstituteBuffalo, United StatesContact: Igor Puzanov, MDTaking people
  • Sarah Cannon Research Institute at HealthONEDenver, United StatesContact: Gerald Falchook, MD, MSTaking people
  • Yale Cancer CenterNew Haven, United StatesContact: Harriet Kluger, MDTaking people
  • HonorHealth Research InstituteScottsdale, United StatesContact: Justin Moser, MDTaking people
  • Moffitt Cancer CenterTampa, United StatesContact: Ahmad Tarhini, MDTaking people

About the trial

What the trial wants to find out

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned; the exact design of the Phase 2 study elements with respect to formulation and pre-treatment will be determined after completion of the Phase 1 study portion of the trial.

The 4 groups in the trial

  • Phase 1a, Dose EscalationTreatment being tested

    In the Phase 1a monotherapy study, the starting dose of ST-067 will be 30 μg/kg, with a total of 7 dose level cohorts planned. The starting dose for the IV infusion monotherapy dosing will be 60 µg/kg. Patients will be treated every week with ST-067 in all cohorts. The DLT period is 28 days after the initial dose of ST-067. According to the mTPI schema initially there will be 3 patients per cohort until the first DLT is observed at which point cohorts will be expanded according to the predetermined mTPI design. Up to 12 patients will be treated at the RP2D.

    Treatment: ST-067

  • Phase 2, ExpansionTreatment being tested

    Phase 2 will enroll patients aged 18 years or older diagnosed with the following solid tumors: melanoma, renal cell carcinoma (RCC), triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and microsatellite instability-high (MSI-Hi) tumors at the RP2D.

    Treatment: ST-067

  • Phase 1a, Dose Escalation, ST-067 SC + Obinutuzumab Pre-treatmentTreatment being tested

    Patients will be treated every week with ST-067 in all cohorts. The DLT period is 28 days after the initial dose of ST-067. According to the mTPI schema initially there will be 3 patients per cohort until the first DLT is observed at which point cohorts will be expanded according to the predetermined mTPI design. The starting dose for ST-067 with obinutuzumab pre-treatment will be 120µg/kg. Obinutuzumab will be administered at 1000 mg daily via IV infusion on 2 consecutive days, with the first dose given at least 7 days prior to first dose of SC ST-067.

    Treatment: ST-067 and Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]

  • Phase 1 combination therapyTreatment being tested

    Phase 1 dose escalation in combination with pembrolizumab will start at a dose of 30 µg/kg of ST-067 and 200 mg every 3 weeks of pembrolizumab. Patients will be treated every week with ST-067 and every three weeks with pembrolizumab. The MTD will be determined based on the mTPI design.

    Treatment: ST-067 and pembrolizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies
Plain-language title
Tests ST-067 alone or with pembrolizumab in adults with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 November 2024